检索结果-南通市图书馆

Sodium glucose cotransporter-2 inhibitors and heart disease:Current perspectives

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Cardiology 2024年第5期16卷 240-259页

作者： Sunetra Mondal Subhodip Pramanik Vibhu Ranjan Khare Cornelius James Fernandez Joseph M Pappachan Department of Endocrinology NRS Medical CollegeKolkata 700020West BengalIndia Department of Endocrinology Neotia Getwel Multispecialty HospitalsSiliguri 734010West BengalIndia Department of Endocrinology and Metabolism Pilgrim HospitalUnited Lincolnshire Hospitals NHS TrustBoston PE219QSUnited Kingdom Department of Endocrinology and Metabolism Lancashire Teaching Hospitals NHS TrustPreston PR29HTUnited Kingdom Faculty of Science Manchester Metropolitan UniversityManchester M156BHUnited Kingdom Faculty of Biology Medicine&HealthThe University of ManchesterManchester M139PLUnited Kingdom

Sodium glucose cotransporter-2 inhibitors(sglt-2i)are antidiabetic medications with remarkable cardiovascular(CV)benefits proven by multiple randomised controlled trials and real-world *** drugs are also useful in the prevention of CV disease(CVD)in patients with diabetes mellitus(DM).Although DM as such is a huge risk factor for CVD,the CV benefits of sglt-2i are not just because of antidiabetic *** molecules have proven beneficial roles in prevention and management of nondiabetic CVD and renal disease as *** are various molecular mechanisms for the organ protective effects of sglt-2i which are still being *** understanding of the role of sglt-2i in prevention and management of CVD is important not only for the cardiologists but also for other specialists caring for various illnesses which can directly or indirectly impact care of heart *** clinical review compiles the current evidence on the rational use of sglt-2i in clinical practice.

关键词： sglt2 inhibitors sglt2i Cardiovascular disease Heart failure Atherosclerotic cardiovascular disease Diabetic kidney disease

Cardioprotective mechanism of sglt2 inhibitor against myocardial infarction is through reduction of autosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Protein & Cell 2022年第5期13卷 336-359页

作者： Kai Jiang Yue Xu Dandan Wang Feng Chen Zizhuo Tu Jie Qian Sheng Xu Yixiang Xu John Hwa Jian Li Hongcai Shang Yaozu Xiang Shanghai East Hospital School of Life Sciences and TechnologyTongji UniversityShanghai 200092China State Key Laboratory of Bioreactor Engineering Shanghai Key Laboratory of New Drug DesignEast China University of Science and TechnologyShanghai 200237China Section of Cardiovascular Medicine Department of Internal MedicineYale Cardiovascular Research CenterYale University School of MedicineNew HavenCT 06511USA Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing Dongzhimen Hospital Affiliated to Beijing University of Chinese MedicineBeijing 100700China

Sodium-glucose cotransporter 2(sglt2)inhibitors reduce cardiovascular mortality in patients with diabetes mellitus but the protective mechanism remains *** we demonstrated that the sglt2 inhibitor,Empagliflozin(EMPA),suppresses cardiomyocytes autosis(autophagic cell death)to confer cardioprotective *** myocardial infarction(Ml)mouse models with and without diabetes mellitus,EMPA treatment significantly reduced infarct size,and myocardial fibrosis,thereby leading to improved cardiac function and *** the context of ischemia and nutritional glucose deprivation where autosis is already highly stimulated,EMPA directly inhibits the activity of the Na^(+)/H^(+)exchanger 1(NHE1)in the cardiomyocytes to regulate excessive *** of NHE1 significantly rescued glucose deprivation-induced *** contrast,overexpression of NHE1 aggravated the cardiomyocytes death in response to starvation,which was effectively rescued by EMPA ***,in vitro and in vivo analysis of NHE1 and Beclin 1 knockout mice validated that EMPA s cardioprotective effects are at least in part through downregulation of autophagic *** findings provide new insights for drug development,specifically targeting NHE1 and autosis for ventricular remodeling and heart failure after Ml in both diabetic and non-diabetic patients.

关键词： myocardial infarction sglt2 inhibitors empagliflozin cardioprotection NHE1 autosis

Canagliflozin Regulates Ferroptosis, Potentially via Activating AMPK/PGC-1α/Nrf2 Signaling in HFpEF Rats

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Cardiovascular Innovations and Applications 2022年第3期7卷 92-101页

作者： Sai Ma Lili He Qingjuan Zuo Guorui Zhang Yifang Guo Department of Pain Hebei General HospitalShijiazhuang 050051HebeiChina Department of Geriatric Cardiology Hebei General HospitalShijiazhuang 050051HebeiChina Department of Cardiology The Third Hospital of Shijiazhuang City affiliated with Hebei Medical UniversityShijiazhuang 050011HebeiChina

Aims:Sodium-glucose cotransporter-2(sglt2)inhibitors have been found to ameliorate major adverse cardiovascular events in patients with heart failure with preserved ejection fraction(HFpEF),but the exact mechanism is *** is a form of programmed ***,we verified that canagliflozin(CANA)ameliorates heart function in HFpEF rats,partly by regulating ferroptosis,which may be activated by AMPK/PGC-1α/Nrf2 ***:An HFpEF model was established and subjected to CANA *** pressure was monitored,and echocardiography was performed at the 12th *** examination was performed,and expression of ferroptosis-associated proteins and AMPK/PGC-1α/Nrf2 signaling related proteins was ***:CANA had an antihypertensive effect and increased E/A ratios in HFpEF *** pathology was ameliorated,on the basis of decreased cross-sectional area and intercellular ***-CoA synthetase longchain family member 4(ACSL4)expression increased,whereas ferritin heavy chain 1(FTH1)expression decreased in HFpEF rats,which showed iron *** reversed changes in ACSL4 and FTH1,and decreased iron accumulation,but did not alter glutathione peroxidase 4(GPX4)*** expression of AMPK/PGC-1α/Nrf2 signaling related proteins and heme oxygenase 1(HO-1)in the HFpEF group decreased but was reverted after CANA ***:CANA regulates ferroptosis,potentially via activating AMPK/PGC-1α/Nrf2 signaling in HFpEF rats.

关键词： ferroptosis heart failure sglt2 inhibitors AMPK

Protective Effect of sglt2 Inhibitor on D-Galactose-Induced Senescence in Mice and Its Mechanism

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Biosciences and Medicines 2023年第5期11卷 286-302页

作者： Zijun Ma Meilin Xu Kaiqin Jin Guangfu Zhu Xin Chen Department of Geriatric Medicine Dongfeng General Hospital Hubei University of Medicine Shiyan China Department of Cardiovascular Medicine The Second Affiliated Hospital of Anhui Medical University Hefei China

Objective: To observe the cerebral protective effect of dagliflozin, a sodium-glucose co-transport protein 2 (sglt2) inhibitor, in aging mice and to explore its molecular mechanism. Methods: 1. 66 male C57BL/6 mice were divided into control group (13) and model group (53), and the model group was moulded by subcutaneous injection of D-galactose into the back of the neck, while the control group was treated with equal amount of saline for 8 weeks. The weight of each group of mice was observed and recorded every 7 days, and two groups of mice were randomly selected for frozen sections of brain tissue at the end of the modelling period to verify the aging model. 2. After the aging model was successfully established, the aging groups were divided into 5 groups: model group, dagliflozin-treated group (high and low dose), and dagliflozin + ex527-inhibited group (high and low dose). Fasting blood glucose was measured in each group every 2 weeks for 8 weeks. At the end of treatment, Morris water maze was performed at the end of the treatment. After execution of the mice, the organ indices of heart, brain, liver, kidney and spleen were measured;the levels of superoxide dismutase (SOD) and malondialdehyde (MDA) in serum were determined. Results: After the successful establishment of the aging model, it was found that during the treatment phase of dagliflozin. 1) The organ indices of mice in the aging group were significantly lower than those of other groups, and no significant hypoglycemia was observed throughout the treatment process. 2) In the water maze test, mice in the aging group had a significantly longer latency in the plateau phase compared to the control and treatment groups, while the number of times the mice crossed the original plateau and the percentage of time spent exploring the original plateau quadrant were reduced after the plateau was removed. 3) The nerve cells in the aging mice were disorganized and the nuclei of the mice were deeply stained;the dagliflo

关键词： Aging Neurodegenerative Diseases sglt2 inhibitors Oxidative Stress SIRT1 Signalling Pathway

Metabolic and Renal Protective Benefits of Magnesium Supplementation in the Long-Term Management of Patients with Type 2 Diabetes Mellitus

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2023年第2期13卷 163-177页

作者： Richard Evers Katholi Marcella Rene Ervin Prairie Educational and Research Cooperative Department of Pharmacology Southern Illinois School of Medicine Springfield USA Prairie Educational and Research Cooperative Springfield USA

Magnesium deficiency is common in patients with type 2 diabetes mellitus (type 2 DM). When adequate magnesium supplementation is chronically given, patients with type 2 DM appear to have improved glucose control and may have delayed chronic complications. In addition, magnesium supplementation may slow the progression of chronic kidney disease (CKD) and decrease the risk of contrast-induced nephropathy in patients with type 2 DM. Keeping serum magnesium at 2.0 mEq/L or greater appears to accomplish these benefits for patients with type 2 DM. Periodically measuring serum magnesium and estimated glomerular filtration rate (eGFR) allows a physician to adjust the supplemental magnesium dose to accomplish these therapeutic goals while avoiding hypermagnesemia.

关键词： Hypomagnesemia Contrast-Induced Nephropathy Renal Function sglt2 inhibitors Type 2 Diabetes Mellitus